Evidence map›Paper›PMID 30039283›Full record

ReviewClinical & experimental metastasis2018

Future perspectives: cancer metastases.

Stanley P Leong, Jonathan S Zager

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & experimental metastasis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Bioactivity of Synthesized Trifluoromethyl Thioxanthone Analogues.Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Stanley P LeongCalifornia Pacific Medical Center and Research Institute, San Francisco, CA, USA. leongsx@cpmcri.org.
Jonathan S ZagerDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The sentinel lymph node (SLN) is the initial metastatic site for the majority of solid cancers. In some cases, cancer cells may bypass the SLNs and enter the vascular channels directly to spread to the systemic sites. Metastatic progression is an orderly process. During the process of metastasis, complex biochemical and molecular mechanisms are involved being subjected to the host influence, in particular, the immune system. With more detailed understanding of the genomic and molecular characteristics of cancer both from the primary site and its metastases, the pathways of cancer growth and spread within the cancer microenvironment may be further elucidated.

Indexed as

HumansNeoplasm MetastasisNeoplasmsSentinel Lymph NodeCancer growthCancer metastasisCancer microenvironment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.